Loading people...
Andrew Hack is a Managing Director at Bain Capital Life Sciences, a leading investment firm focused on the biotechnology, pharmaceutical, and medical device sectors. He is known for his expertise in identifying and nurturing innovative life sciences companies.
Andrew Hack primarily invests in companies within the biotechnology, pharmaceutical, and medical device industries. His focus includes novel drugs, advanced medical technologies, and disruptive healthcare services that offer significant potential for patient impact and market growth.
Andrew Hack works as a Managing Director at Bain Capital Life Sciences. This firm is part of Bain Capital, a globally recognized private investment firm.
Andrew Hack is a Managing Director at Bain Capital Life Sciences in Boston, Massachusetts, focusing on global investments across the biopharmaceutical, medical device, and diagnostic sectors. Prior to joining the firm in 2019, he served as Chief Financial Officer of Editas Medicine from 2015 to 2019, guiding the CRISPR biotechnology company through its initial public offering in February 2016. Previously, he managed a healthcare hedge fund as a portfolio manager at Millennium Management and worked as a securities analyst. He holds an MD and a PhD in molecular genetics and cell biology, alongside an AB in biology, from the University of Chicago. He currently serves on the board of directors for multiple biopharmaceutical companies, including Dynavax Technologies, Mersana Therapeutics, and Nuvalent. His career bridges clinical expertise and financial strategy to scale life sciences enterprises.
Andrew Hack stands as a prominent figure in the life sciences investment landscape, serving as a Managing Director at Bain Capital Life Sciences. In this pivotal role, he is instrumental in identifying and cultivating high-potential companies within the biotechnology, pharmaceutical, and medical device sectors. His work at Bain Capital Life Sciences involves leading strategic investments aimed at fostering innovation and bringing transformative healthcare solutions to patients worldwide. Hack's deep industry knowledge and extensive experience make him a key driver in the firm's mission to support groundbreaking scientific advancements.
Hack's investment focus at Bain Capital Life Sciences is broad yet specialized, encompassing a wide array of therapeutic areas and technological platforms. He seeks out companies developing novel drugs, advanced medical technologies, and disruptive healthcare services that have the potential to significantly impact patient outcomes and market dynamics. His analytical rigor, combined with a profound understanding of scientific and clinical development, allows him to assess complex opportunities and guide portfolio companies through critical growth phases.
Before joining Bain Capital Life Sciences, Andrew Hack built a distinguished career spanning both the medical and financial fields. He previously held the position of portfolio manager at HealthCor Management, LP, a highly respected healthcare-focused hedge fund. Prior to his tenure at HealthCor, Hack honed his expertise as a biotechnology equity analyst at leading financial institutions, including Credit Suisse and UBS. This experience provided him with a comprehensive understanding of market dynamics and valuation within the life sciences industry.
Beyond his financial acumen, Hack possesses a robust medical and scientific background. He completed an internal medicine residency at the prestigious Brigham and Women's Hospital. Academically, he earned his M.D. from Harvard Medical School and a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University, following his undergraduate studies at Stanford University. This unique blend of clinical, scientific, and financial expertise positions Andrew Hack as an exceptionally well-rounded investor capable of navigating the intricate challenges and opportunities within the life sciences sector. His contributions at Bain Capital Life Sciences continue to shape the future of healthcare innovation.
